← Leaderboards
Zdravka O. Medarova
Massachusetts General Hospital
$10,579,501
Attributed
$13,896,717
Total exposure
8
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.4M · FY2007–25$2M$1.5M$1M$500K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$13,896,717 · 8
By mechanism
R01$8,268,890 · 3
R44$4,308,833 · 2
R00$739,381 · 1
R56$296,923 · 1
K99$282,690 · 1
Top collaborators
- Anna Moore12 shared
- Judy Carmody1 shared
Most similar at Massachusetts General Hospital
Same institution · by research overlap
- Anna Moore$29,133,166
- Tayyaba Hasan$21,611,486
- Sandra Orsulic$4,151,521
- David E Sosnovik$15,139,691
- Howard H. Chen$2,536,240
Others in their field
Top investigators on “Magnetic Resonance Imaging”
- Michael W Weiner · Northern California Institute Res &Educ$151,227,246
- Paul S. Aisen · Cognition Therapeutics, Inc.$114,102,468
- Reisa A. Sperling · Banner Health$112,709,449
- Randall J Bateman · Washington University$108,056,165
- Peter Gordon Gillespie · Oregon Health And Science University$104,808,120
- Joseph E Robertson · Oregon Health & Science University$93,739,249
Research focus
Magnetic Resonance ImagingChemotherapyIn VivoMouse ModelBasePeptidesTumorImageMalignant NeoplasmsNeoplastic CellUptakeNanoparticleDetectionSpecificityMalignant Breast NeoplasmDrug KineticsResponseMediatingAnimal ModelCancer TherapyTissuesImaging ProbeCancer PatientClinical Trials
Grant awards (28)
Phase I Clinical Testing of a First-in-Class Therapy against Metastatic Cancer$988,765
R44 · FY2025 · CA · contact PI
Phase I Clinical Testing of a First-in-Class Therapy against Metastatic Cancer$1,011,207
R44 · FY2024 · CA · contact PI
Clinical Development of First-in-Class Therapy for Metastatic Breast Cancer$870,684
R44 · FY2023 · CA · contact PI
Clinical Development of First-in-Class Therapy for Metastatic Breast Cancer$1,129,316
R44 · FY2022 · CA · contact PI
Clinical Development of First-in-Class Therapy for Metastatic Breast Cancer$308,861
R44 · FY2021 · CA
Therapy for Metastatic breast cancer based on micro RNA silencing$586,520
R01 · FY2020 · CA · contact PI
Therapy for Metastatic breast cancer based on micro RNA silencing$568,924
R01 · FY2019 · CA · contact PI
Therapy for Metastatic breast cancer based on micro RNA silencing$572,534
R01 · FY2018 · CA · contact PI
Predictive Cancer Diagnostics and Therapy Response$552,370
R01 · FY2018 · CA
In vivo methodology for the discovery and validation of miRNA biomarkers in cancer$296,923
R56 · FY2018 · CA · contact PI
Predictive Cancer Diagnostics and Therapy Response$552,368
R01 · FY2017 · CA
Predictive Cancer Diagnostics and Therapy Response$552,368
R01 · FY2016 · CA
MicroRNA Therapy for Lymph Node Metastatic Breast Cancer$395,711
R01 · FY2016 · CA · contact PI
Predictive Cancer Diagnostics and Therapy Response$552,368
R01 · FY2015 · CA
MicroRNA Therapy for Lymph Node Metastatic Breast Cancer$395,711
R01 · FY2015 · CA · contact PI
Predictive Cancer Diagnostics and Therapy Response$589,368
R01 · FY2014 · CA
MicroRNA Therapy for Lymph Node Metastatic Breast Cancer$383,839
R01 · FY2014 · CA · contact PI
MicroRNA Therapy for Lymph Node Metastatic Breast Cancer$371,967
R01 · FY2013 · CA · contact PI
MicroRNA Therapy for Lymph Node Metastatic Breast Cancer$396,090
R01 · FY2012 · CA · contact PI
Multi-Parameter Monitoring of Breast Cancer Progression and Therapeutic Response$488,276
R01 · FY2011 · CA
Target-Specific Imaging and Delivery of siRNA to Tumors$241,530
R00 · FY2011 · CA · contact PI
Target-Specific Imaging and Delivery of siRNA to Tumors$249,000
R00 · FY2010 · CA · contact PI
Multi-Parameter Monitoring of Breast Cancer Progression and Therapeutic Response$94,933
R01 · FY2010 · CA
Multi-Parameter Monitoring of Breast Cancer Progression and Therapeutic Response$598,918
R01 · FY2009 · CA
Target-Specific Imaging and Delivery of siRNA to Tumors$248,851
R00 · FY2009 · CA · contact PI
Multi-Parameter Monitoring of Breast Cancer Progression and Therapeutic Response$616,625
R01 · FY2008 · CA
Target-Specific Imaging and Delivery of siRNA to Tumors$141,750
K99 · FY2008 · CA · contact PI
Target-Specific Imaging and Delivery of siRNA to Tumors$140,940
K99 · FY2007 · CA · contact PI